Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Filings indexed 481 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
Regulatory Filings
2026-05-13 English
ARS - Spero Therapeutics, Inc. (0001701108) (Filer)
Annual Report
2026-04-27 English
DEF 14A - Spero Therapeutics, Inc. (0001701108) (Filer)
Proxy Solicitation & Information Statement
2026-04-27 English
4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
Director's Dealing
2026-02-10 English
4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
Director's Dealing
2026-02-10 English
4 Filing
Director's Dealing
2026-02-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.